Skip to content

US · SNN · MEDICAL - DEVICES

Smith & Nephew plc (SNN) intrinsic value and stock valuation

$29.83as of 2026-11-21 · Mkt cap 12.65B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Smith & Nephew plc DCF and intrinsic value

InvestorsCraft values SNN with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from SNN’s statements →

Smith & Nephew plc Graham Number

Graham Number: $19.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Watford, HRT WD18 8YE smith-nephew.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$6.16B+6.2% 5y CAGRd
20112025
Net income
$625M+6.9% 5y CAGRd
20112025
Free cash flow
$852M+11.6% 5y CAGRd
20112025
Total equity
$5.29B+0% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$6.16B$5.81B$5.55B$5.22B$5.21B
Operating income$794M$657M$425M$450M$593M
Net income$625M$412M$263M$223M$524M
EPSd$1.43M$940K$1.2M$509.7K$1.19M
Operating cash flow$1.29B$987M$608M$468M$877M
Capital expenditure-$-433M-$-381M-$-427M-$-358M-$-408M
Free cash flow$852M$606M$181M$110M$469M
Total assets$10.5B$10.4B$9.99B$9.97B$10.9B
Total debt$3.33B$3.32B$3.08B$2.87B$3.34B
Net debt$2.77B$2.7B$2.78B$2.52B$2.05B
Total equity$5.29B$5.27B$5.22B$5.26B$5.57B
Cash and short-term investments$557M$619M$302M$350M$1.29B
Income statement
20252024202320222021
Revenue$6.16B$5.81B$5.55B$5.22B$5.21B
Cost of revenue$1.96B$1.73B$1.65B$1.52B$1.51B
Gross profit$4.21B$4.08B$3.9B$3.7B$3.7B
Research and development expenses$346M$343M$339M$345M$356M
Selling, general and administrative expenses$3.04B$2.9B$2.83B$2.71B$2.64B
Other expenses$31M$175M$297M$198M$112M
Operating expenses$3.41B$3.42B$3.47B$3.25B$3.11B
Cost and expenses$5.37B$5.15B$5.12B$4.77B$4.62B
Interest income$28.1M$24M$34.1M$14M$6M
Interest expense$141.3M$150.1M$132.5M$80M$80M
Depreciation and amortization$459M$449M$473M$492M$507M
Ebitda$1.34B$1.34B$1.21B$1.15B$1.22B
Operating income$794M$657M$425M$450M$593M
Total other income/expenses, net-$-15M-$-159M-$-135M-$-215M-$-7M
Income before tax$779M$498M$290M$235M$586M
Income tax expense$154M$86M$27M$12M$62M
Net income$625M$412M$263M$223M$524M
Weighted average shares outstanding$433.4M$438.3M$217.8M$437.6M$438.5M
Weighted average diluted shares outstanding$436.5M$438.3M$218.4M$437.6M$438.9M
Balance sheet
20252024202320222021
Cash and short-term investments$557M$619M$302M$350M$1.29B
Net receivables$1.43B$1.21B$1.06B$1.03B$971M
Inventory$2.12B$2.39B$2.4B$2.21B$1.84B
Total current assets$4.1B$4.42B$4.03B$3.86B$4.42B
Property, plant and equipment, net$1.64B$1.42B$1.47B$1.46B$1.51B
Goodwill and intangible assets$3.99B$4.06B$4.1B$4.27B$4.39B
Long-term investments$151M$16M$24M$58M$380M
Total non-current assets$6.35B$5.93B$5.96B$6.11B$6.5B
Total assets$10.5B$10.4B$9.99B$9.97B$10.9B
Accounts payable$1.16B$1.08B$1.02B$1.03B$1.04B
Short-term debt$150M$63M$765M$160M$491M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.6B$1.53B$2.27B$1.72B$2.13B
Long-term debt$3.18B$3.26B$2.32B$2.71B$2.85B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.57B$3.56B$2.5B$2.99B$3.22B
Capital lease obligations$216M$196M$199M$196M$197M
Total liabilities$5.17B$5.09B$4.77B$4.71B$5.35B
Common stock$175M$175M$175M$175M$177M
Retained earnings$5.32B$5.02B$4.91B$5.03B$5.23B
Accumulated other comprehensive income (loss)$20M$0.00-$-385M-$-439M-$-328M
Total equity$5.29B$5.27B$5.22B$5.26B$5.57B
Total investments$151M$16M$24M$58M$380M
Total debt$3.33B$3.32B$3.08B$2.87B$3.34B
Net debt$2.77B$2.7B$2.78B$2.52B$2.05B
Cash flow statement
20252024202320222021
Net income$625M$412M$263M$223M$524M
Depreciation and amortization$573M$555M$527M$548M$563M
Stock-based compensation$43M$40M$39M$40M$41M
Change in working capital$33M-$-123M-$-227M-$-510M-$-232M
Accounts receivable-$-175M-$-81M-$-49M-$-103M-$-81M
Inventory$208M-$-42M-$-178M-$-407M-$-151M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$1.29B$987M$608M$468M$877M
Investments in property, plant and equipment-$-433M-$-381M-$-427M-$-358M-$-408M
Acquisitions, net-$-9M-$-186M-$-21M-$-113M-$-285M
Net cash used for investing activities-$-406M-$-569M-$-448M-$-472M-$-691M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-502M$0.00$0.00-$-158M$0.00
Dividends paid-$-330M-$-327M-$-327M-$-327M-$-329M
Net cash used for financing activities-$-955M-$-86M-$-200M-$-926M-$-645M
Net change in cash-$-62M$317M-$-44M-$-941M-$-466M
Cash at end of period$557M$617M$300M$344M$1.29B
Operating cash flow$1.29B$987M$608M$468M$877M
Capital expenditure-$-433M-$-381M-$-427M-$-358M-$-408M
Free cash flow$852M$606M$181M$110M$469M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Smith & Nephew plc

        Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

        CEO
        Deepak S Nath
        Employees
        18.36K
        Beta
        0.69

        Explore

        Frequently asked questions

        What is the intrinsic value of Smith & Nephew plc (SNN)?

        Smith & Nephew plc (SNN) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SNN undervalued?

        SNN trades at a price of $29.83 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.